Payment overview · 2025
General Payments
$332.44
7 reported records · 5 companies
Healthcare provider profile · identity verified
Al William Robaina, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · APOLLO BEACH, FL · NPI 1780657817
Verified facts
What the public records show
CMS Open Payments records show Al William Robaina, M.D. received $332.44 in general payments during 2025 across 7 reported records.
Novo Nordisk Inc accounted for 42.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Paxlovid.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $140.34 | 42.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $136.83 | 41.2% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $22.27 | 6.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.21 | 6.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $11.79 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $332.44 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $140.34 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $136.83 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $11.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 121 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 72 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 15 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
121 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
81 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
92 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 535 | 150 |
| Gabapentin | Gabapentin | 457 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 451 | 94 |
| Alprazolam | Alprazolam | 375 | 49 |
| Oxycodone Hcl | Oxycodone Hcl | 367 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 364 | 94 |
| Lisinopril | Lisinopril | 302 | 74 |
| Losartan Potassium | Losartan Potassium | 293 | 82 |
| Omeprazole | Omeprazole | 289 | 56 |
| Trazodone Hcl | Trazodone Hcl | 271 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 266 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 264 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 234 | 55 |
| Furosemide | Furosemide | 230 | 61 |
| Metformin Hcl | Metformin Hcl | 229 | 67 |
| Ibuprofen | Ibuprofen | 215 | 37 |
| Clonazepam | Clonazepam | 200 | 26 |
| Montelukast Sodium | Montelukast Sodium | 174 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 172 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 170 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 165 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 165 | 34 |
| Famotidine | Famotidine | 152 | 28 |
| Divalproex Sodium | Divalproex Sodium | 148 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 147 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 147 | 16 |
| Baclofen | Baclofen | 140 | 22 |
| Glimepiride | Glimepiride | 140 | 34 |
| Lamotrigine | Lamotrigine | 140 | 13 |
| Simvastatin | Simvastatin | 138 | 39 |
| Sertraline Hcl | Sertraline Hcl | 134 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 131 | 35 |
| Carvedilol | Carvedilol | 129 | 37 |
| Mounjaro | Tirzepatide | 121 | 14 |
| Lactulose | Lactulose | 120 | 18 |
| Alendronate Sodium | Alendronate Sodium | 114 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 108 | 15 |
| Risperidone | Risperidone | 104 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 104 | 20 |
| Meloxicam | Meloxicam | 98 | 29 |
| Prednisone | Prednisone | 95 | 39 |
| Tramadol Hcl | Tramadol Hcl | 95 | 28 |
| Allopurinol | Allopurinol | 93 | 17 |
| Celecoxib | Celecoxib | 93 | 20 |
| Levetiracetam | Levetiracetam | 93 | 11 |
| Eliquis | Apixaban | 92 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 91 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 29 |
| Potassium Chloride | Potassium Chloride | 82 | 21 |
| Trulicity | Dulaglutide | 81 | 15 |
| Lorazepam | Lorazepam | 78 | 15 |
| Buspirone Hcl | Buspirone Hcl | 77 | 11 |
| Lacosamide | Lacosamide | 76 | suppressed |
| Olanzapine | Olanzapine | 76 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 73 | 15 |
| Ozempic | Semaglutide | 72 | 17 |
| Azithromycin | Azithromycin | 70 | 42 |
| Temazepam | Temazepam | 70 | suppressed |
| Linzess | Linaclotide | 67 | 12 |
| Glipizide | Glipizide | 63 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 63 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 18 |
| Primidone | Primidone | 60 | suppressed |
| Mirtazapine | Mirtazapine | 56 | suppressed |
| Spironolactone | Spironolactone | 55 | suppressed |
| Sucralfate | Sucralfate | 55 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 54 | suppressed |
| Naproxen | Naproxen | 54 | 13 |
| Oxcarbazepine | Oxcarbazepine | 54 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 53 | suppressed |
| Topiramate | Topiramate | 53 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 52 | suppressed |
| Ramelteon | Ramelteon | 52 | suppressed |
| Valsartan | Valsartan | 52 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 49 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 48 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 18 |
| Chlorthalidone | Chlorthalidone | 47 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 47 | suppressed |
| Nifedipine Er | Nifedipine | 47 | 11 |
| Amoxicillin | Amoxicillin | 46 | 35 |
| Jardiance | Empagliflozin | 46 | 11 |
| Pregabalin | Pregabalin | 46 | 12 |
| Benztropine Mesylate | Benztropine Mesylate | 44 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 44 | suppressed |
| Tradjenta | Linagliptin | 44 | suppressed |
| Fenofibrate | Fenofibrate | 43 | suppressed |
| Nystatin | Nystatin | 43 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 42 | suppressed |
| Cephalexin | Cephalexin | 41 | 32 |
| Morphine Sulfate Er | Morphine Sulfate | 40 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 40 | suppressed |
| Atenolol | Atenolol | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | 15 |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 38 | suppressed |
| Diazepam | Diazepam | 37 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 21 |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Methadone Hcl | Methadone Hcl | 30 | suppressed |
| Clobazam | Clobazam | 29 | suppressed |
| Ketoconazole | Ketoconazole | 29 | 14 |
| Mupirocin | Mupirocin | 29 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 20 |
| Zonisamide | Zonisamide | 28 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 27 | suppressed |
| Finasteride | Finasteride | 27 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Valproic Acid | Valproic Acid | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 17 |
| Nabumetone | Nabumetone | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Haloperidol | Haloperidol | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 12 |
| Diclofenac Potassium | Diclofenac Potassium | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Xifaxan | Rifaximin | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Levocarnitine | Levocarnitine | 15 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 12 | 12 |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Clarithromycin Er | Clarithromycin | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Ongentys | Opicapone | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 11 |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Promethegan | Promethazine Hcl | 12 | suppressed |
| Risperidone Odt | Risperidone | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $332.44 · 7 records | Novo Nordisk Inc | AIRSUPRA, Arikayce, MOUNJARO, Ozempic, PAXLOVID, Rybelsus, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error